Merck has completed its previously announced, $1.85 billion acquisition of Pandion Therapeutics Inc., it announced Thursday.
The Kenilworth-based drugmaker paid $60 per share for Pandion through a subsidiary, and Pandion has now become a wholly owned subsidiary of Merck.
The deal was first announced in February.
